Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis

Background: Cystic fibrosis (CF) is associated with worsening of depression and anxiety symptoms. Elexacaftor/tezacaftor/ivacaftor (Trikafta®), a cystic fibrosis transmembrane regulator (CFTR) modulator approved in 2019, significantly improves lung function, decreases pulmonary exacerbations, and im...

書誌詳細
出版年:	Therapeutic Advances in Respiratory Disease
主要な著者:	Lijia Zhang, Dana Albon, Marieke Jones, Heather Bruschwein
フォーマット:	論文
言語:	英語
出版事項:	SAGE Publishing 2022-12-01
オンライン･アクセス:	https://doi.org/10.1177/17534666221144211

類似資料

Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis
著者:: Sofia Campos Silva, 等
出版事項: (2025-06-01)

Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
著者:: Harish Pudukodu, 等
出版事項: (2024-09-01)

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
著者:: Steven J Edwards, 等
出版事項: (2025-05-01)

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
著者:: Marta Solís García, 等
出版事項: (2025-02-01)

Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
著者:: Tahuanty A. Pena, MD, MS, 等
出版事項: (2025-02-01)

Effect of elexacaftor–tezacaftor–ivacaftor modulator on lung structure in cystic fibrosis
著者:: V. Fainardi, 等
出版事項: (2023-09-01)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
著者:: Ngoc Hoa Truong, 等
出版事項: (2025-05-01)

Cystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor
著者:: Charlotte Mouliade, 等
出版事項: (2025-10-01)

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
著者:: Hazel Ozuna, 等
出版事項: (2025-01-01)

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
著者:: Vito Terlizzi, 等
出版事項: (2025-03-01)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
著者:: L. Gómez-Ganda, 等
出版事項: (2024-06-01)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
著者:: Sarah Allgood, 等
出版事項: (2023-09-01)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
著者:: Linus Piehler, 等
出版事項: (2023-04-01)

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
著者:: Seth A. Reasoner, 等
出版事項: (2024-02-01)

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
著者:: Andrea Gramegna, 等
出版事項: (2023-06-01)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
著者:: Nikoletta Kapouni, 等
出版事項: (2023-03-01)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
著者:: Payal Patel, 等
出版事項: (2023-02-01)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
著者:: Dirk Westhölter, 等
出版事項: (2023-02-01)

A real-life study of elexacaftor-tezacaftor-ivacaftor therapy in people with cystic fibrosis in Brazil
著者:: L.Z. Salomão, 等
出版事項: (2023-11-01)

Disproportionate Rates of Liver Injury in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor in Queensland, Australia
著者:: Ellie Johnson, 等
出版事項: (2025-01-01)

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis
著者:: Carlos Martín de Vicente, 等
出版事項: (2024-12-01)

Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis
著者:: Dirk Westhölter, 等
出版事項: (2024-01-01)

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
著者:: Christian Martin, 等
出版事項: (2023-12-01)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
著者:: Eva Choong, 等
出版事項: (2022-08-01)

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis
著者:: Thomas Keens, 等
出版事項: (2024-04-01)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
著者:: Marika Comegna, 等
出版事項: (2021-07-01)

Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
著者:: Kadambari Vijaykumar, 等
出版事項: (2024-04-01)

CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
著者:: Hanna Crow, 等
出版事項: (2022-12-01)

Evolution of Lung Disease Studied by Computed Tomography in Adults with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
著者:: Susana Hernández-Muñiz, 等
出版事項: (2025-04-01)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del
著者:: Heledd H. Jarosz-Griffiths, 等
出版事項: (2024-01-01)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del.
著者:: Heledd H Jarosz-Griffiths, 等
出版事項: (2024-01-01)

Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy
著者:: Yasmin Hilliam, 等
出版事項: (2024-08-01)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
著者:: Mafalda Bacalhau, 等
出版事項: (2023-03-01)

Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry
著者:: Mordechai Pollak, 等
出版事項: (2025-08-01)

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
著者:: Sarah J. Morgan, 等
出版事項: (2024-10-01)

Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
著者:: Angela Pepe, 等
出版事項: (2025-02-01)

Short-term effects of elexacaftor/tezacaftor/ivacaftor in pediatric cystic fibrosis patients in Brazil: a case series
著者:: Marta Amor Barbosa, 等
出版事項: (2024-12-01)

Increased fat mass and obesity risk after elexacaftor–tezacaftor–ivacaftor therapy in young adults with cystic fibrosis
著者:: Ana Merino Sánchez-Cañete, 等
出版事項: (2024-11-01)

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor–Tezacaftor–Ivacaftor
著者:: Kimberly Tantuco, MD, 等
出版事項: (2024-02-01)

Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment
著者:: Hanna Schmidt, 等
出版事項: (2023-06-01)